This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 | G71.0 |
| Special Copayment Reduction | V012 · 5 years |
| A. Synonyms | Severe [Duchenne] muscular dystrophy, benign [Becker] muscular dystrophy, X-linked muscular dystrophy |
| B. Adult onset | Low (DMD) / moderate (BMD) — DMD onset at age 3–5; BMD onset from the teens to adulthood, with walking possibly maintained beyond age 40 |
| 1. History | 1861: Duchenne (Duchenne de Boulogne) first described progressive muscle atrophy; 1955: Becker classified the milder phenotype separately; 1987: Kunkel et al. discovered the dystrophin protein |
| 2. Causes | Mutations in the DMD gene located at Xp21.2 (deletions 65%, duplications 6–10%, point mutations 25–30%); complete dystrophin deficiency (DMD) or partially preserved function (BMD) |
| 3. Genetics | X-linked recessive; DMD/BMD distinguished by the reading-frame rule; risk of cardiomyopathy in about 2/3 of female carriers |
| 4. Epidemiology | DMD 1 in 3,500–5,000 male births; BMD 1 in 18,450; more than about 300,000 worldwide |
| 5. Pathophysiology | Disruption of the dystrophin-associated protein complex (DAPC) → sarcolemmal instability → repeated injury and necrosis → replacement by fat and fibrous tissue |
| 6. Symptoms | Proximal muscle weakness (Gowers sign), calf pseudohypertrophy, gait abnormality, cardiomyopathy, respiratory failure; BMD has a milder course than DMD |
| 7. Signs | Gowers sign, waddling gait (Trendelenburg gait), toe walking, lumbar lordosis, scoliosis, calf pseudohypertrophy; serum CK elevated tens to hundreds of times |
| 8. Screening | Newborn CK screening (some countries); first-line serum CK measurement in boys with developmental delay or gait abnormality; prenatal genetic testing when there is a family history |
| 9. Diagnosis | Serum CK (10,000–20,000 IU/L) → MLPA/NGS-based genetic testing → muscle biopsy (dystrophin immunohistochemistry); echocardiography and pulmonary function tests in parallel |
| 10. Treatment | Corticosteroids (standard treatment), exon-skipping therapy (eteplirsen, golodirsen, etc.), nonsense mutation read-through (ataluren), gene therapy (Elevidys, FDA 2023), givinostat (HDAC inhibitor, FDA 2024) |
| 11. Prognosis | DMD: without steroid treatment, loss of ambulation around age 12 and cardiopulmonary failure in the 20s–30s; with steroid treatment, ambulation extended by several years; BMD: walking can be maintained beyond age 40 |
| 12. Prevention | Genetic counseling for carrier women, preimplantation genetic diagnosis (PGT), prenatal diagnosis (CVS/amniocentesis); prevention of complications through cardiopulmonary monitoring of confirmed patients |
| References | 10 key PMIDs/DOIs |
The first systematic description of Duchenne muscular dystrophy (DMD) began in 1861 with a paper by the French neurologist Guillaume-Benjamin-Amand Duchenne de Boulogne reporting 13 boys with progressive proximal muscle weakness. Duchenne was the first to use a biopsy needle called the 'aiguille' to biopsy muscle at the time, pathologically demonstrating fatty infiltration and fibrosis of the muscle. Subsequently, in 1879, William Gowers of the United Kingdom independently described the same disease and reported in detail the 'Gowers sign', a characteristic climbing maneuver.
In 1955, the German neurologist Peter Emil Becker and his colleague Kiener first described a separate X-linked phenotype with a much milder clinical course, which today is called Becker muscular dystrophy (BMD). DMD and BMD were long regarded as different diseases, but in 1982 Monaco et al. discovered the same gene locus at Xp21 associated with both diseases, revealing that they are a phenotypic spectrum caused by a single gene. In 1987, Louis Kunkel's group identified the gene product, the dystrophin protein, which became a turning point in muscular dystrophy research.
From the 1990s, the reading-frame rule was formulated, establishing that deletion mutations that disrupt the reading frame present as DMD and those that maintain it present as BMD. From the 2000s, antisense oligonucleotide (ASO)–based exon-skipping strategies were validated preclinically and clinically, and in 2023 the US Food and Drug Administration (FDA) conditionally approved the gene therapy Elevidys (delandistrogene moxeparvovec-rokl), opening the era of disease-modifying treatment. In 2024, the HDAC inhibitor givinostat also received FDA approval, further expanding treatment options.
DMD/BMD is caused by mutations in the DMD gene located on the short arm of the X chromosome (Xp21.2). The DMD gene is the largest single gene in the human genome, comprising 79 exons over a genomic region of about 2.4 Mb. Because of this enormous gene size, the spontaneous mutation rate is very high, and about 1/3 of patients arise from new (de novo) mutations.
The frequencies by mutation type are as follows: deletions of one or more exons 65%, exon duplications 6–10%, and point mutations (including nonsense mutations) and small insertions/deletions 25–30%. The exon 45–55 and exon 2–20 regions are known as 'hotspots' where deletions cluster. Of these, mutations whose reading frame can be restored by exon 51 skipping account for about 13% of all DMD and are the target of the FDA-approved drug eteplirsen.
The molecular distinction between DMD and BMD is explained by the reading-frame rule. When deletions or duplications disrupt the mRNA reading frame, a premature stop codon forms and dystrophin is almost completely lost, producing the DMD phenotype; when the reading frame is maintained, a functionally shortened dystrophin is produced, resulting in the relatively mild BMD phenotype. However, exceptions to the reading-frame rule are observed in about 10–15% of all mutations, so there are limits to predicting phenotype by the simple rule alone.
DMD/BMD follows an X-linked recessive inheritance pattern. Thus the full clinical phenotype appears in hemizygous males, while heterozygous females are mostly carriers with mild or no clinical symptoms. However, about 2/3 of carrier women may show muscle symptoms such as calf pseudohypertrophy, elevated serum CK and muscle weakness, and cardiomyopathy is known to develop in about 7–17%. This is due to skewed X-chromosome inactivation (lyonization).
Key points in genetic counseling are as follows. Sons of a carrier mother have a 50% chance of being affected, and daughters a 50% chance of being carriers. Because the proportion of new (de novo) mutations is high, the possibility cannot be excluded even with a negative family history. Gonadal mosaicism exists, so recurrence can occur in the same parents. After confirmation, carrier testing of the maternal family must be recommended.
Preimplantation genetic testing (PGT) is available in conjunction with in vitro fertilization when the familial mutation has been identified, and for prenatal diagnosis, genetic testing via chorionic villus sampling (CVS, 10–13 weeks of gestation) or amniocentesis (15–18 weeks of gestation) is standard. MLPA (Multiplex Ligation-dependent Probe Amplification) is highly sensitive for detecting exon deletions and duplications, and point mutations are confirmed by Sanger sequencing or next-generation sequencing (NGS).
DMD is the most common X-linked myopathy, occurring at a frequency of 1 per 3,500–5,000 male births. Worldwide, about 20,000 newborns are diagnosed with DMD each year, and more than about 300,000 people are currently estimated to be affected worldwide. The incidence of BMD is lower than that of DMD, reported as 1 per 18,000–30,000 male births. It is distributed evenly worldwide regardless of race, ethnicity or geographic location.
In Korea, according to rare disease statistics, the total number of patients with muscular dystrophy (G71.0) is on the order of several thousand, with DMD accounting for the largest share. In Special Copayment Reduction registration it is managed under the V012 (muscular dystrophy) code and requires renewal every 5 years. In some countries that perform newborn CK screening, early diagnosis rates have increased, but in Korea universal newborn CK screening is not currently mandatory, and the average age at diagnosis is around 4–5 years.
Female carriers exist at a frequency of about 1/5,000, and some, as 'manifesting carriers', show muscle weakness or cardiomyopathy. There is no father-to-son transmission, so the sons of an affected male patient do not become carriers.
Dystrophin acts as a 'mechanical shock absorber' that links actin, a cytoskeletal protein of the muscle fiber, to the dystrophin-associated protein complex (DAPC) of the cell membrane. The DAPC is composed of dystroglycan, sarcoglycan, syntrophin, dystrobrevin and others; it disperses the mechanical stress generated during muscle contraction and coordinates cell signaling.
When dystrophin is deficient, the entire DAPC becomes unstable, and sarcolemmal damage from repeated muscle contraction is accelerated. Extracellular calcium enters through the damaged sarcolemma, leading in cascade to calpain activation, mitochondrial dysfunction and increased reactive oxygen species (ROS). Cycles of necrosis and regeneration then repeat, but as the regenerative capacity of satellite cells is gradually exhausted, muscle is replaced by fat and fibrous tissue.
The same mechanism acts in the myocardium and respiratory muscles, so dilated cardiomyopathy and restrictive ventilatory failure progress. Short isoforms of dystrophin (Dp71, Dp140) are also expressed in the brain, and their deficiency is associated with the cognitive impairment, attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder observed in some patients. The intelligence quotient (IQ) of DMD patients is known to be about 1 standard deviation below the normal mean.
DMD typically begins at age 3–5 with proximal muscle weakness. Symptoms that parents notice first include slow running, difficulty climbing up and down stairs, frequent falls, and the Gowers maneuver of pushing on the knees with the arms when rising from the floor. Pseudohypertrophy of the calf and triceps muscles is observed in more than 90%, reflecting replacement by fat and connective tissue rather than actual muscle. Scoliosis, lumbar lordosis and equinus contracture progress, and without steroid treatment ambulation is lost at around an average age of 12 (10–14).
After loss of ambulation, cardiomyopathy and respiratory failure become the main causes of death. Dilated cardiomyopathy begins to be detected on echocardiography after age 10, and myocardial involvement is confirmed in almost all patients after age 18. Chronic respiratory failure progresses, beginning with nocturnal hypoventilation and sleep apnea, and moves from nocturnal mechanical ventilation to daytime use. Dysphagia, constipation and reduced gastrointestinal motility are also common symptoms.
BMD involves the same gene abnormality, but partial dystrophin function is preserved, so symptoms are much milder and onset is later. Some patients maintain independent walking into their 40s–50s without loss of ambulation, and some BMD patients complain only of reduced exercise tolerance, myalgia (exercise-induced myalgia) or muscle cramps as their main symptoms and are diagnosed through an incidental CK test. However, the incidence of cardiomyopathy in BMD does not differ greatly from DMD, so regular cardiac evaluation is essential.
Characteristic signs of DMD on physical examination are as follows. Gowers' sign: when rising from the floor, the patient first gets prone and then pushes the trunk up using the arms and legs, reflecting weakness of the pelvic and proximal lower limb muscles. Trendelenburg gait (waddling gait): because of gluteus medius weakness, the pelvis tilts toward the unaffected side during walking and the whole body sways. Calf pseudohypertrophy: the gastrocnemius, replaced by fat and connective tissue, instead appears prominent. Increased lumbar lordosis: a compensatory posture for iliopsoas and gluteal weakness. Equinus contracture: shortening of the Achilles tendon causes walking with the heels raised.
A characteristic laboratory finding is elevation of serum creatine kinase (CK) to tens to hundreds of times normal or more (usually 10,000–20,000 IU/L or higher). AST and ALT are also often elevated from a muscle source, which can be confused with liver disease, and LDH and aldolase are also elevated. Electromyography (EMG) shows a myopathic pattern with small, short, polyphasic motor unit potentials (small, short, polyphasic MUAPs) and spontaneous activity potentials. MRI shows a symmetric pattern of fat replacement of muscle.
Electrocardiogram (ECG) abnormalities are observed in more than 90% of DMD patients, typically increased R waves in the right precordial lead (V1) and deep Q waves in leads I and aVL. Pulmonary function tests show a progressive restrictive pattern (reduced FVC, normal FEV1/FVC), and when FVC falls to 30% of predicted or less, airway clearance assistance and initiation of mechanical ventilation should be considered.
The simplest method for early screening for DMD/BMD is measurement of serum CK. CK is performed as a first-line test when developmental delay, gait abnormality or unexplained elevation of liver enzymes is observed in a boy. In DMD, CK is generally elevated more than 50 times normal, so DMD can be practically excluded if CK is normal. However, CK may decrease somewhat with loss of muscle mass after loss of ambulation.
Newborn screening: some countries (Wales in the UK, some US states, some regions of China) perform newborn serum CK screening, with the aims of early diagnosis and provision of genetic counseling. However, universal adoption is controversial because of false-positive rates, psychological burden and the limited therapeutic interventions that can yet be started in infancy. With recent advances in gene therapy and exon-skipping therapy, the value of early diagnosis has increased, and discussion of expanding newborn screening is becoming active.
When there is a family history: when a woman identified as a carrier becomes pregnant, fetal genetic testing is performed via chorionic villus sampling (CVS) or amniocentesis. Preimplantation genetic testing (PGT-M) combined with in vitro fertilization is the most direct way to prevent implantation of an affected embryo. Cardiac and muscle assessment of the carrier woman herself is also performed periodically.
The diagnosis of DMD/BMD is made by a combination of clinical findings, serum CK, genetic testing and muscle biopsy. Recently, the trend is to perform genetic testing first and to perform muscle biopsy as a complement only when results are negative or their interpretation is uncertain.
Step 1 — serum CK measurement: performed as the first-line test in suspected patients. Usually 10,000–25,000 IU/L in DMD and in the 1,000–10,000 IU/L range in BMD. Step 2 — genetic testing: MLPA first tests for exon deletions and duplications; if negative, an NGS panel (myopathy panel or whole-exome analysis) is used to search for point mutations and small insertions/deletions. The molecular diagnostic yield is over 95%. Step 3 — muscle biopsy: performed when genetic testing does not establish the diagnosis or pathologic confirmation is needed. Dystrophin immunohistochemistry (IHC) and Western blot assess the presence and amount of protein expression. DMD: dystrophin negative or trace; BMD: reduced or abnormal bands.
Ancillary tests: electromyography (EMG) is useful for confirming a myopathic pattern, but its diagnostic value has decreased compared with the era before genetic testing. Muscle MRI (T1 fat-suppressed sequences) helps define the pattern of muscle involvement and select the biopsy site. Echocardiography and ECG are performed from the time of confirmation, with cardiac evaluation every 6–12 months thereafter. Pulmonary function tests (PFT) are recommended every 6 months in cooperative patients aged 6 or older.
Treatment of DMD/BMD is divided into standard treatment that slows disease progression and prevents complications, and precision treatment that targets the genetic defect.
Standard treatment — corticosteroids: Prednisolone (0.75 mg/kg/day) or deflazacort (0.9 mg/kg/day) is established as the international standard treatment. It is effective in maintaining muscle strength, extending the ambulatory period (by an average of 2–3 years) and preserving against scoliosis and loss of respiratory function. Major adverse effects include weight gain, osteoporosis, growth suppression, mood disorders and cataracts, requiring regular monitoring. Vamorolone, which received FDA approval in 2023, is a new agent with steroid-like anti-inflammatory effects and an improved adverse-effect profile.
Exon-skipping therapy: a strategy in which antisense oligonucleotides (ASOs) induce skipping of a specific exon to restore the reading frame, converting DMD to a BMD-like phenotype. FDA-approved drugs: ① eteplirsen (exon 51 skipping) — approved 2016, applicable to about 13% of all DMD; ② golodirsen (exon 53 skipping) — approved 2019; ③ viltolarsen (exon 53 skipping) — approved 2020; ④ casimersen (exon 45 skipping) — approved 2021. However, confirmatory evidence of the clinical efficacy of these drugs remains limited, and they were licensed through the accelerated approval pathway.
Ataluren: a mechanism that reads through nonsense mutations (premature stop codons) to produce full-length dystrophin. It previously received conditional authorization in Europe, but in March 2025 the European Commission refused renewal, so it is currently not approved in the EU.
Gene therapy — Elevidys: conditional FDA approval in 2023 (for ambulatory patients aged 4–5). It uses an AAV rh74 vector to deliver a shortened micro-dystrophin throughout the musculature. It aims for sustained protein expression with a single intravenous injection. Monitoring for immune responses (excluded if AAV neutralizing antibodies are present) and acute hepatotoxicity is needed.
Givinostat: FDA approval in 2024. A histone deacetylase (HDAC) inhibitor that promotes muscle regeneration and suppresses fibrosis and inflammation. Used together with corticosteroids in ambulatory DMD patients aged 6 or older.
Supportive care: ACE inhibitors or angiotensin receptor blockers (prophylactic administration recommended from age 10), noninvasive positive pressure ventilation (BiPAP/CPAP), airway clearance assistance (MI-E, cough assist device), rehabilitation (physical therapy, occupational therapy), assistive devices and wheelchairs, orthopedic surgery (scoliosis correction, Achilles tendon lengthening), nutrition and weight management, and psychosocial support should be provided in a multidisciplinary manner.
Before the introduction of corticosteroid treatment, the natural course of DMD had a grave prognosis, with loss of ambulation at an average age of 9–12 and death from cardiopulmonary failure in the early 20s. However, with combined steroid treatment, nocturnal mechanical ventilation, cardiac drug therapy and active rehabilitation, many patients now survive beyond their 30s. Some reports show increasing survival into the 40s, and studies have been published showing that cohorts since the 1990s reach an average life expectancy in the 30s–40s.
Respiratory failure accounts for 70–80% of deaths, and the rest are due to heart failure or arrhythmia from cardiomyopathy. In BMD, independent walking is often maintained until age 40–50, and some retain walking ability beyond their 60s, but cardiomyopathy progresses similarly to DMD, with a risk of sudden death. The main cause of death in BMD patients is heart failure.
In terms of cognitive function, about 30–40% of DMD patients have learning disabilities, delayed language development, ADHD or autism spectrum disorder. This is related to deficiency of Dp71 (a short dystrophin isoform expressed mainly in the brain) and is particularly frequent with mutations beyond exon 63. Appropriate special education and psychological support have a large impact on quality of life.
DMD/BMD is a single-gene disease, and fundamental prevention is achieved through genetic counseling and prenatal or preimplantation diagnosis. When there is a family history: carrier women receive genetic counseling before pregnancy and can avoid implantation of affected embryos through PGT-M (preimplantation genetic testing for monogenic disorders). If already pregnant, fetal genetic testing is performed by CVS (10–13 weeks of gestation) or amniocentesis (15–18 weeks of gestation), and continuation or termination of the pregnancy can be chosen depending on whether the fetus is affected.
Expansion of newborn screening can advance the start of treatment through early diagnosis, and its importance is growing especially in the era of gene therapy. In patients already confirmed, secondary prevention of complications is important. Cardiomyopathy: prophylactic ACE inhibitors from age 10 and echocardiographic follow-up every 6 months. Respiratory complications: initiation of nocturnal BiPAP before FVC falls to 30% or less, and a routine of airway clearance. Osteoporosis: vitamin D and calcium supplementation during steroid treatment and regular dual-energy X-ray absorptiometry (DEXA). Joint contractures: active stretching and wearing orthoses (AFO) to prolong the period of preserved function.
Management of carrier women: cardiac evaluation (echocardiography, ECG) is performed at least every 5 years, and cardiac drug therapy is started early when symptoms appear. Immediate evaluation is needed for cardiopulmonary symptoms during exercise or rapid loss of muscle strength.